Nymox Pharmaceutical Corporation logo
Nymox Pharmaceutical Corporation NYMX

Annual report 2024
added 04-25-2026

report update icon

Nymox Pharmaceutical Corporation Income Statement 2011-2026 | NYMX

Annual Income Statement Nymox Pharmaceutical Corporation

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - - 143 M 193 M 197 M 131 M 170 M 136 M 86.4 M 13.7 M 195 M 221 M 261 M

Shares

- - - 82 M 73.8 M 68.8 M 60.5 M 52.6 M 46.2 M 37.4 M 35.3 M 34.1 M 33.2 M 32.7 M

Historical Prices

0.2 0.2 0.2 1.75 2.61 2.86 2.17 3.23 3.54 2.75 0.64 5.45 5.83 7.91

Net Income

- - - -12.5 M -11.7 M -13.2 M -10.6 M -13.4 M -13.1 M -17.9 M -4.59 M -4.91 M -7.63 M -9.65 M

Revenue

- - - - 5 K 116 K 299 K 224 K 284 K 2.76 M 2.95 M 3.36 M 3.07 M 3.11 M

Cost of Revenue

- - - - 4 K 58 K 138 K 149 K 173 K 160 K - - - -

Gross Profit

- - - - 1 K 58 K 161 K 75 K 111 K 2.6 M 2.78 M 2.87 M 2.82 M 2.82 M

Operating Income

- - - -12.5 M -11.7 M -13.3 M -10.6 M -13.2 M -12.9 M -17.7 M - - - -

EBITDA

- - - -12.5 M -11.7 M -13.3 M -10.6 M -13.2 M -12.9 M -17.7 M -4.72 M -4.88 M -7.58 M -9.61 M

Operating Expenses

- - - - 11.7 M 13.4 M 10.8 M 13.3 M 13 M 20.3 M 7.5 M 7.76 M 10.4 M 12.4 M

General and Administrative Expenses

- - - 5.85 M 3.6 M 6.01 M 4.12 M 5.43 M 6.18 M 11.6 M 2.82 M 1.76 M 1.97 M 2.83 M

All numbers in USD currency

Quarterly Income Statement Nymox Pharmaceutical Corporation

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - - 86 M - 83.8 M 81.5 M 78 M - 74.7 M 71.7 M 71.6 M - 70 M 68.4 M 67 M - 61.5 M 59.3 M 57.1 M - 53.3 M 51.5 K 49.7 K - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- - - -5.09 M - -3.3 M -3.99 M -2.44 M - -4.16 M -2.94 M -2.62 M - -2.46 M -5.14 M -2.87 M - -2.79 M -2.42 M -2.66 M - - - -2.81 M - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - - - - - - - - 5 K - 39 K 20 K 30 K - 40 K 88 K 152 K - 31 K 9 K 78 K - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - 4 K - 16 K 7 K 29 K - 25 K 24 K 59 K - 33 K 27 K 45 K - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - - - -3.29 M -3.98 M -2.43 M - -4.14 M -2.93 M -2.63 M - -2.51 M -5.2 M -2.91 M - -2.81 M -2.42 M -2.66 M - -4.57 M -2.6 M -2.76 M - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - -3.29 M -3.98 M -2.43 M - -4.14 M -2.93 M -2.63 M - -2.51 M -5.2 M -2.91 M - -2.81 M -2.42 M -2.66 M - -4.57 M -2.6 M -2.76 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - 5.07 M - - - 2.43 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- - - 740 K - 1.46 M 1.91 M 1 M - 909 K 773 K 1.08 M - 1.02 M 2.88 M 1.18 M - 1.17 M 935 K 794 K - - 7 K 1.12 M - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Nymox Pharmaceutical Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.9 -2.33 % $ 6.62 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 21.96 -0.68 % $ 3.64 B usaUSA
RedHill Biopharma Ltd. RedHill Biopharma Ltd.
RDHL
$ 1.02 -0.49 % $ 428 M israelIsrael
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 6.4 4.4 % $ 63.3 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 21.41 1.9 % $ 1 B usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 12.26 3.72 % $ 1.62 B australiaAustralia
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
BioNTech SE BioNTech SE
BNTX
$ 105.46 -0.09 % $ 27.2 B germanyGermany
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.08 0.25 % $ 436 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.26 1.75 % $ 2.96 B usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.44 -5.88 % $ 383 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.06 -3.64 % $ 12.9 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 2.95 -3.28 % $ 296 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.91 -1.36 % $ 4.79 M israelIsrael
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA